A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Overweight, Obesity

In brief

This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.

Key facts

Study ID

NCT00392925

Run by

AstraZeneca

People needed

177

Starts

2006-10-01

Expected to finish

2007-09-01

Last updated by the study team

2015-04-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is obese (Body Mass Index [BMI]>=30kg/m\^2 and <=35kg/m\^2); or overweight (BMI>=27kg/m\^2 and <30kg/m\^2) with abdominal obesity, based on the following: *waist circumference >102 cm if male, *waist circumference >88 cm if female
• Is a nonsmoker (has not smoked for at least 6 months prior to the study)
• Consumes a morning and evening meal each day

You may not qualify if…

• Is diagnosed with type 2 diabetes
• Is currently enrolled or plans to enroll in a diet, weight loss, or exercise program with the specific intent of losing weight (subjects who have been following an exercise regimen resulting in stable weight maintenance for at least 2 months prior to enrollment are eligible for study inclusion)
• Has been treated over the past 2 months, is currently treated, or is expected to require or undergo treatment with any of the following medications: *antiobesity agents (prescription or over-the-counter), *antipsychotic agents, *antiepileptic agents, *antidepressant agents, *drugs that directly affect gastrointestinal motility
• Has received any investigational drug within 30 days or within a period corresponding to 5 half-lives of that drug, whichever is greater, prior to this study starting
• Has previously received treatment with recombinant leptin or pramlintide

Where it is running

• Research Site — DeLand, Florida, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Indianapolis, Indiana, United States
• Research Site — Overland Park, Kansas, United States
• Research Site — Baton Rouge, Louisiana, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Edina, Minnesota, United States
• Research Site — Butte, Montana, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Portland, Oregon, United States
• Research Site — Salt Lake City, Utah, United States
• Research Site — Olympia, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.